title: New developments in thyroid cancer.
abstract: Thyroid cancer is common but rarely deadly. Unfortunately, when the disease becomes refractory to radioactive iodine (RAI), few effective treatment options remain. This situation is changing, however, with the availability of multitargeted tyrosine kinase inhibitors. Cabozantanib and vandetanib, both recently FDA-approved for advanced or metastatic disease, have more than doubled progression-free survival in medullary thyroid cancer. New agents in the pipeline may yield even better outcomes, as discussed by Dr. Robert I. Haddad at the NCCN 18th Annual Conference.
authors.affiliation: Harvard Medical School and Head and Neck Oncology Program at Dana-Farber Cancer Institute and Brigham and Women's Cancer Center, Boston, Massachusetts 02115, USA.
authors.forename: Robert I
authors.initials: RI
authors.lastname: Haddad
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D018276:Carcinoma, Medullary / Q000628:therapy; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors